profit from every $100 of sales.
$0$100
Globus Medical
$72.14-0.22% today
-14.1% in 1 year
1-year low $71.051-year high $96.82
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $17.79 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Globus Medical sold, what it kept, and what it did with the cash.
Sales went from $1.02 billion in 2022 to $2.94 billion in 2025, with $538 million of profit last year.
SalesProfit
Globus Medical handed back 52% of the cash it generated last year.
Buybacks $300M
Free cash flow 2025$579M
Bought back its own shares$300M
Paid as dividends–
Cash vs. debt$526M vs. $119M
Globus Medical vs. similar companies
Globus Medical grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Globus Medical | 17.8× · Fair price | ||
 Abbott Laboratories | 28.8× · Fair price | ||
 Medtronic | 27.4× · Fair price | ||
 Stryker | 36.3× · Expensive | ||
 Edwards Lifesciences | 57.4× · Expensive |
AI analysis
An AI analyst reads Globus Medical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 789 | 958 | 1,023 | 1,568 | 2,519 | 2,939 | |
| 572 | 719 | 759 | 1,020 | 1,484 | 1,981 | |
| – | – | 236 | 201 | 219 | 537 | |
| – | – | 305 | 347 | 473 | 814 | |
| 102 | 149 | 190 | 123 | 103 | 538 | |
| 1.01 | 1.44 | 1.85 | 1.07 | 0.75 | 3.92 | |
| 72.4% | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% | |
| – | – | 23.1% | 12.8% | 8.7% | 18.3% | |
| 13.0% | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,679 | 1,957 | 2,076 | 5,086 | 5,252 | 5,303 |
| Cash | 239 | 193 | 150 | 467 | 784 | 526 |
| Total debt | – | – | 6 | 520 | 537 | 119 |
| Total liabilities | 173 | 216 | 230 | 1,088 | 1,074 | 730 |
| 1,506 | 1,741 | 1,846 | 3,998 | 4,177 | 4,573 | |
| 101 | 104 | 103 | 115 | 138 | 137 | |
| – | – | 10.1% | 3.5% | 3.7% | 9.0% | |
| 6.8% | 8.6% | 10.3% | 3.1% | 2.5% | 11.8% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 199 | 276 | 178 | 243 | 521 | 753 | |
| 64 | 57 | 74 | 78 | 115 | 174 | |
| 135 | 219 | 104 | 165 | 405 | 579 | |
| Dividends paid | – | – | – | – | – | – |
| 105 | – | 144 | 226 | 86 | 300 | |
| 27 | 31 | 33 | 53 | 54 | 50 |
Valuation
- 17.8×
- 16.1×
- 0.57
- 2.2×
- 3.3×
- 16.5×
- 11.3×
- 6.1%
- 5.6%
- 0.0%
Profitability
- 67.4%
- 18.3%
- 18.3%
- 28.6%
- 9.3%
- 6.7%
- 13.0%
- 10.8%
- 11.0%
- 6.1%
Growth
- +30.1%
- +31.2%
- +45.3%
- –
- +10.1%
Financial health
- -0.5×
- 0.03
- 2.1%
- –
- 4.26
- 2.95
- 0.57
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 33%of 952
Top 27%of 883
Top 29%of 601
Top 18%of 888
Top 17%of 987
What analysts expect
- Average price target
- $110.67
- Range
- $100.00 – $115.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 1.12 | 0.92 | +21.7% |
| Feb 24, 2026 | 1.28 | 1.06 | +20.8% |
| Nov 6, 2025 | 1.18 | 0.78 | +51.1% |
| Aug 7, 2025 | 0.86 | 0.76 | +13.2% |
| May 8, 2025 | 0.68 | 0.74 | −8.6% |
| Feb 20, 2025 | 0.84 | 0.74 | +13.5% |
| Nov 5, 2024 | 0.83 | 0.65 | +28.3% |
| Aug 6, 2024 | 0.75 | 0.68 | +10.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
60Pass
Benjamin Graham
72Pass
Philip Fisher
77Pass
Peter Lynch
98Pass
Joel Greenblatt
32No pass
Charlie Munger
57No pass
Terry Smith
60Pass
Questions about Globus Medical
Is Globus Medical a good stock to buy?
A solid business at a fair price. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Globus Medical AI analysis
What does Globus Medical do?
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It is in Medical Devices, based in Audubon, PA, United States, with 6,000 employees.
Does Globus Medical pay a dividend?
No. Globus Medical does not pay a dividend at the moment; in 2025 it returned $300 million to shareholders by buying back its own shares.
Is Globus Medical stock halal?
Yes. Globus Medical passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Globus Medical stock done over the past year?
Down 14.1% over the past twelve months, to $72.14. It traded between $71.05 and $96.82 and is 25.5% below its high.
Who are Globus Medical's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Globus Medical's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.